The board of Sudarshan Pharma Industries approved the acquisition of a 9.50% stake in MedTherapy Biotechnology Inc., a US-based cancer cell and gene therapy company, on September 5, 2026.

The transaction involves purchasing 24,23,675.64 equity shares of common stock, par value US$0.0001 per share. This move is designed to establish a presence in the United States market and access existing customer bases and distribution networks.

Deal Structure and Promoter Interest

The acquisition will be funded through cash consideration in US dollars. The cost is based on the prevailing valuation norms for MedTherapy Biotechnology. The company aims to complete the acquisition by March 31, 2027.

Promoters of Sudarshan Pharma are also participating in the deal:

• Mr. Hemal Mehta (Chairman & Managing Director) will acquire 1.50% of the issued share capital.
• Mr. Sachin Mehta (Joint Managing Director) will acquire an additional 1.50% of the issued share capital.

Both promoters will acquire 3,82,685.63 equity shares each. The disclosure confirms that this transaction does not fall under related-party transactions.

Regulatory Approvals and Due Diligence

The deal requires approval from the Reserve Bank of India under the Foreign Exchange Management Act (FEMA) 1999. Specifically, it seeks clearance under the Foreign Exchange Management (Overseas Investment) Rules, 2022, via the automatic route.

Legal and commercial due diligence must be concluded before the transaction closes. All relevant FEMA regulations will be addressed during this process.

About the Target Entity

MedTherapy Biotechnology Inc. is incorporated in Delaware, USA, with its technology development site in Boston. Founded in 2018 by experts from Harvard and former Novartis executives, it operates as an end-to-end integrated CAR-T Cell CDMO.

The target maintains a commercial-scale GMP manufacturing facility in New Delhi, India. Its mission focuses on making cancer cell and gene therapy treatments affordable and accessible to patients globally.

What the Numbers Show

The combined promoter interest of 3.00% alongside the corporate stake of 9.50% indicates a significant strategic alignment between Sudarshan Pharma’s leadership and the target entity. This structure suggests confidence in the long-term value of entering the US biotechnology sector through MedTherapy’s established infrastructure.

Sudarshan Pharma Industries has scheduled its 18th Annual General Meeting for Tuesday, September 22, 2026. The meeting will be conducted through video conferencing or other audio-visual means at 3:00 pm IST.

The primary agenda includes the adoption of audited financial statements for the fiscal year ended March 31, 2026. Shareholders will also vote on the re-appointment of Dr. Anil Ghogare as a director.

Director Re-Appointment

Dr. Anil Ghogare retires by rotation and offers himself for re-appointment as a Non-Executive Non-Independent Director. He was originally appointed to the board on November 10, 2023.

Dr. Ghogare holds a PhD in Pharmaceutical Chemistry from Mumbai University and an M.Tech from the Indian Institute of Technology, New Delhi. He possesses 37 years of experience in fermentation technology and serves as a regulatory consultant for pharmaceutical plant design and technology transfers.

Meeting Logistics

The company will provide remote e-voting facilities through National Securities Depository Limited. The voting period begins on Saturday, September 19, 2026, at 9:00 am and ends on Monday, September 21, 2026, at 5:00 pm.

The record date for determining voting eligibility is Tuesday, September 15, 2026. Members can attend the meeting via video conferencing starting 15 minutes before the scheduled time. Proxy appointments are not available for this meeting.